Dr Lal Pathlabs Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹874 Cr +19.6% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
DL

Dr Lal Pathlabs

Q4 FY26Healthcare Services

Dr Lal Pathlabs Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹703Cr
+16.6% YoY
+6.5% QoQ
Net profit
₹132Cr
−15.4% YoY
+45.1% QoQ
Margin
27%
−1 pp YoY
0 pp QoQ
Price₹1,894
Market cap₹31.8K Cr
P/E56.6

The short version

Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually). The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery.

From Dr Lal Pathlabs's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually).
  • Patient volume growth is expected to improve gradually, supported by expansion of labs and collection networks.
  • Recent quarter showed an 8.2% volume growth, but annualized growth (~5.3%) is a better indicator.
  • Growth is broad-based across regions, with sustained double-digit growth in Delhi NCR and improving growth in Suburban business.
  • Expansion in Tier 3 and Tier 4 geographies contributing positively without diluting realizations.
  • Increased focus on health packages and specialized testing, including the preventive healthcare brand Swasthfit (27% revenue contribution).
  • New labs and network additions (12-15 labs planned next year) will support volume growth.

2 more points from Dr Lal Pathlabs's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dr Lal Pathlabs said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY27 capex guidance is Rs. 100 crore - Rs. 120 crore.
  • Capex includes both maintenance and growth investments.
  • Growth capex planned for opening 12 to 15 new labs next year (14 labs added in current year).
  • Investments in a precision diagnostic lab with high-end complex testing equipment.
  • Incorporation of a subsidiary in Dubai as part of international expansion, considering both organic and inorganic opportunities including potential M&A in Middle East.
  • Some investments planned in radiology centers – slow and calibrated growth approach on radiology expansion, including integrated high-end radiology centers in Delhi NCR and possibly Tier 2 towns.

2 more points from Dr Lal Pathlabs's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dr Lal Pathlabs said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided from the Q4 & FY26 Earnings Conference Call of Dr. The discussion primarily focuses on operational performance, acquisitions, margin profiles, expansion plans, patient volume growth, capex guidance, and margin outlook. - Focus is on network expansion (labs and collection centers), including franchising in Suburban areas. - Acquisition of Shahbazkers Diagnostic Centre to strengthen presence in Mumbai is mentioned. - Capex for FY27 is guided at Rs. 100-120 crore, supporting organic and inorganic growth.

2 more points from Dr Lal Pathlabs's call on order book

Create a free account to keep reading this call

Dr Lal Pathlabs — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Dr Lal Pathlabs Q4 FY26 results — key figures

Dr Lal Pathlabs Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue703603+16.6%660+6.5%
Operating profit (EBITDA)187169+10.7%179+4.5%
Operating margin27%28%-1 pp27%0 pp
Profit before tax160153+4.6%124+29%
Net profit (PAT)132156-15.4%91+45.1%
EPS (₹)7.849.26-15.3%5.40+45.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹874 Cr, net profit ₹194 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Suven Life Sciences (Q4 FY26)

    The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

  • Invicta Diagnostic (Q4 FY26)

    Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…

  • KMC Speciality (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • Star Imaging (Q4 FY26)

    Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dr Lal Pathlabs and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dr Lal Pathlabs Q4 FY26 results?

Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually). The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery.

What is Dr Lal Pathlabs share price analysis?

Dr Lal Pathlabs currently shows a neutral. The stock trades at a P/E of 56.5 with a market cap of ₹31,794 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dr Lal Pathlabs planning capital expenditure?

FY27 capex guidance is Rs. 100 crore - Rs. 120 crore.

Keep Dr Lal Pathlabs on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.